A psychiatry journal has retracted a 2015 meta-analysis on the effectiveness of ketamine for depression after readers found that the article double-counted patients in some studies, thereby inflating the apparent benefits of the drug.
The article, “Efficacy of ketamine in bipolar depression: systematic review and meta-analysis,” was published in the Journal of Psychiatric Practice by a group from the United States and England. But a pair of researchers in Sweden noticed the duplication — and what seems to have been a rather slapdash approach to the work — and pushed to have the paper retracted.
According to the results section of the abstract: Continue reading Ketamine for depression? Paper retracted for error that double-counted clinical trial participants




The maker of a leading over-the-counter antacid has withdrawn its application for approval of the drug in China because a clinical trial of the product in that country was marred by “major protocol deviations.”
Tokyo Women’s Medical University has stripped a researcher of her PhD, following the retraction of a paper — for data duplication — that was based on her thesis.
Journals have retracted all but 19 of the 313 tainted papers linked to three of the most notorious fraudsters in science, with only stragglers left in the literature. But editors and publishers have been less diligent when it comes to delivering optimal retraction notices for the affected articles.
The authors of a 2018 paper on how noisy distractions disrupt memory are retracting the article after finding a flaw in their study.